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http://dxObjectives: The purpose of the present study was to test whether the cumulative knowledge from the field of
transapical transcatheter aortic valve implantation, when incorporated into a structured training and then grad-
ually dispersed by internal proctoring, might eliminate the negative effect of the learning curve on the clinical
outcomes.
Methods: The present study was a retrospective, single-center, observational cohort study of prospectively col-
lected data from all 500 consecutive high-risk patients undergoing transapical transcatheter aortic valve implan-
tation at our institution from April 2008 to December 2011. Of the 500 patients, 28 were in cardiogenic shock.
Differences during the study period in baseline characteristics, procedural and postprocedural variables, and sur-
vival were analyzed using different statistical methods, including cumulative sum charts.
Results: The overall 30-day mortality was 4.6% (95% confidence interval, 3.1%-6.8%) and was 4.0% (95%
confidence interval, 2.6%-6.2%) for patients without cardiogenic shock. Throughout the study period, no sig-
nificant change was seen in the 30-day mortality (Mann-Whitney U test, P ¼ .23; logistic regression analysis,
odds ratio, 0.83 per 100 patients; 95% confidence interval, 0.62-1.12; P ¼ .23). Also, no difference was seen in
survival when stratified by surgeon (30-day mortality, P ¼ .92). An insignificant change was seen toward im-
proved overall survival (hazard ratio, 0.90 per 100 patients; 95% confidence interval, 0.77-1.04; P ¼ .15).
Conclusions: The structured training program can be used to introduce transapical transcatheter aortic valve
implantation and then gradually dispersed by internal proctoring to other members of the team with no concom-
itant detriment to patients. (J Thorac Cardiovasc Surg 2013;145:911-8)The pioneering centers of transcatheter aortic valve implan-
tation (TAVI) reported an important initial negative effect of
the learning curve on the clinical outcomes.1-7 Centers that
introduced a TAVI program later on, such as our
institution,8 have had the opportunity to benefit from the cu-
mulative knowledge of the ‘‘first wave’’ centers. Therefore,
‘‘second wave’’ centers might have a different learning
curve, with a lower negative effect on outcome (ie,
survival).
To test this hypothesis, we conducted a single-center
study of the first 500 consecutive patients undergoing
transapical TAVI. We examined the factors relevant to
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The Journal of Thoracic and Caassessed (‘‘aim of the study’’) whether the cumulative
knowledge from the field incorporated into a structured
training program could be used for introduction of
a novel procedure (transapical TAVI) into clinical prac-
tice and then dispersed by internal proctoring to other
members of the TAVI team without detriment to the clin-
ical outcomes.
METHODS
Study Design
The present study was a retrospective, observational, single-center, co-
hort study of prospectively collected data from all patients who had under-
gone transapical TAVI at the Deutsches Herzzentrum Berlin (Berlin,
Germany) from the beginning of the clinical introduction of transapical
TAVI in April 2008 to December 2011. The study is reported according
to the STrengthening the Reporting of OBservational studies in Epidemiol-
ogy (STROBE) statement and the standardized endpoint definitions for
TAVI clinical trials.9 Our institutional review board approved the present
study.
Patients
All 500 consecutive high-risk patients with aortic valve stenosis who
underwent transapical TAVI at our institution were operated on by the
same heart team and were included in the study (‘‘study cohort’’). All pro-
cedures were performed according to our structured training program and
our TAVI checklist10 (see Part 2, Table 1). All patients or their representa-
tives gave informed consent.rdiovascular Surgery c Volume 145, Number 4 911
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
CUSUM ¼ cumulative sum analysis
IQR ¼ interquartile range
PCI ¼ percutaneous coronary intervention
TAVI ¼ transcatheter aortic valve implantation
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The patient selection, preoperative evaluation, assessment of the diam-
eter of the aortic annulus, valve size selection, and procedural technique
have been previously described in detail8,11 and summarized as the
institutional clinical policies.10
Procedure and Device
Transapical TAVI was performed in the hybrid operating room by the
same TAVI team8 using a principal surgical technique,12 with some modi-
fications,13 according to the institutional policies.10 The attendance of each
member of the team in the hybrid operating room and his or her particular
function during every procedure were precisely recorded in our database.
Balloon-expandable transcatheter stent-prosthetic xenograft valves with
their delivering systems (both Edwards Lifesciences LLC, Irvine, Calif)
were used in all patients. The Edwards Sapien THV valves (size 23 or 26
mm) were used from April 2008 to August 2011 and the Edwards Sapien
XT valves (size 23, 26 or 29 mm) from March 2011 until the end of the
study period (December 2011).
Structured Educational Training Program
The program10 regulates the introduction of TAVI at our institution and
the building and training of the team. It includes a stepwise acquisition of
the tools necessary for preoperative strategic planning, perioperative team
communication, technical aspects of the procedure, and postoperative man-
agement. The program consists of 4 main parts: general principles, team
building, team education and training, and the institutional clinical and pro-
cedural policies.10
Proctoring
Proctoring was divided into external and internal proctoring. Internal
proctoring (‘‘self-proctoring’’) was established on a basis of interaction be-
tween the members of the team (‘‘be proctor and proctored’’), with the aim
of achieving a complete understanding of the fine details of the TAVI pro-
cess.10 It was performed in 4 segments: patient evaluation (segment 1);
measurement of the aortic annulus and valve sizing (segment 2); valve
preparation, technical procedural part, and guiding of the team (segment
3); and postprocedural patient management (segment 4).10
Definition of Outcomes
The primary endpoint was 30-day mortality. It was defined as death
from any cause and irrespective of whether the death occurred from day
0 to day 30 (30th day included) after the index procedure.
The secondary endpoints included survival at follow-up and the intra-
procedural, procedural, and postprocedural variables. Postimplantation
aortic regurgitation, estimated by echocardiography and angiography,
was divided (grade 0-IV) into absent (0), trace (<I), mild (I), moderate
(II), and severe (>II, III, IV).14 Technical procedural complications were
considered surgical complications if they necessitated revision and were di-
rectly caused by surgical technical failure, including pseudoaneurysm of
the apex, revision for bleeding, iatrogenic aortic dissection, valve migra-
tion, and annular rupture.912 The Journal of Thoracic and Cardiovascular SurgFollow-up and Data Collection
Follow-up was 100% complete. The most recent patients had at least 30
days of follow-up. The last update was performed in January 2012. All data
concerning patient comorbidities, morbidity, and mortality were prospec-
tively collected in an electronic database and analyzed. Information about
the deaths of German patients was obtained from the official state admin-
istrative office and/or by direct contact with the patients’ families and by
telephone for the patients from outside Germany.
Assessment of Institutional Learning Curve
The effect of the learning curvewas assessed by the procedural outcome
(the incidence of complications and survival) and by the time effectiveness
of the procedure (operating time duration, amount of contrast medium, ir-
radiation parameters, intensive care unit stay, and hospitalization period).
Cumulative Sum Analysis
Data are also presented graphically as a plot of the outcome (cumulative
sum analysis [CUSUM]). A cumulative failure chart15,16 was used to
evaluate the learning curve. The cumulative sum Sn of deaths until
procedure n was plotted against n.
Statistical Analysis
Continuous variables are presented as the mean standard deviation or
medians and interquartile range (IQR). Categorical variables are described
as numbers and percentages. The 30-day rates during the study period are
presented as percentages with 95% Wilson confidence intervals (CIs).
Changes during the study period were analyzed, with the consecutive num-
ber of the procedure as an independent variable. Trends of the binary vari-
ables during the study period were compared between groups using the
Mann-Whitney U test. The strength of the change was assessed by logistic
regression analysis, checked by the Hosmer-Lemeshow test, and presented
with the odds ratio and 95% CI. To improve readability, the odds ratios are
presented for changes within 100 procedures. The trends of continuous var-
iables were tested by nonparametric Spearman rank correlation (rho) with
the number of the procedure. The Kruskal-Wallis test was used to assess the
difference in the procedure time between different operators. Fisher’s exact
test was used to test for differences in mortality between groups and to as-
sess the binary risk factors for mortality. The Mann-Whitney U test was
used to analyze the continuous risk factors for mortality. Bivariate logistic
regression analysis was applied to analyze the influence of risk factors on
the learning curves of mortality. Overall survival is presented using
Kaplan-Meier curves and was compared between groups using the log-
rank test. A change in overall survival during the study period was analyzed
using Cox regression analysis and is presented as the hazard ratio per 100
procedures with the 95% CI. The data were evaluated using the IBM SPSS
Statistics software, version 19 (SPSS Inc, Armonk, NY).RESULTS
Baseline Characteristics
Patient characteristics. The study cohort consisted of 311
women (62.2%) and 189 men (37.8%). The mean patient
age was 79.5  8.1 years (median, 80.6 years; range,
28.9-98.9 years; IQR, 75.3-84.6 years). The median logistic
European System for Cardiac Operative Risk Evaluation of
the study cohort was 30.4% (IQR 21.0%-48.5%) and the
median Society of Thoracic Surgeons predicted operative
mortality was 12.2% (IQR, 6.7%-21.6%). Of the 500 pa-
tients, 28 (5.6%) were in cardiogenic shock. The mean
follow-up period was 458  368 days, with a range of
0 (in the case of death during the procedural day) to 1363ery c April 2013
TABLE 1. Procedural and postprocedural characteristics
Parameter Value P value*
XT valve 94 (18.8) <.001
23-mm valve 153 (30.6) <.001
26-mm valve 306 (61.2) <.001
29-mm valve 41 (8.2) <.001
Contrast agent (mL) 100 (80-130) .053
Radiation time (min) 6.7 (4.8-10.3) <.001
DAP (mGy m2) 7.0 (5.1-9.6) .007
dPmean (mm Hg) 4 (3-5.8) .002
Aortic valve area (cm2) 2.2 (1.9-2.4) .13
No regurgitation 270 (54.0) .16
Valve redilation 28 (5.6) .38
Second valve 14 (2.8) .006
Procedural time (min) 90 (75-115) <.001
Intraprocedural packed RBCs (U) 0.6 (1.5) .21
Elective PCI 57 (11.4) .95
Elective CPB 25 (5.0) .48
Emergency PCI 4 (0.8) .79
Emergency CPB 10 (2.0) .62
Conversion 4 (0.8) .17
Follow-up (d) 458  368 <.001
ICU time (h) 25.0 (19.8-53.5) .15
In-hospital stay (d) 6.9 (5.0-10.8) <.001
Drainage volume (24 h) 400 (238-625) .91
Total invasive ventilation time (h) 15.1 (2.1-38.4) <.001
Postoperative packed RBCs (U) 1 (0-2) .06
Annulus rupture 6 (1.2)
Aortic dissection 1 (0.2)
Valve migration 1 (0.2)
Revision for bleeding 7 (1.4)
Revision for apical pseudoaneurysm 2 (0.4)
Coronary obstructiony 2 (0.4)
Endocarditis (late) 5 (1.0)
Later aortic valve replacement/second
TAVI
5 (1.0)
Later cardiac surgery (other) 4 (0.8)
Data presented as n (%), median (interquartile range), or mean standard deviation.
DAP, Dose area product; dPmean, mean transvalvular gradient; RBCs, red blood cells;
PCI, percutaneous coronary intervention; CPB, cardiopulmonary bypass; ICU, inten-
sive care unit; TAVI, transcatheter aortic valve implantation. *For changes during
study period (Spearman rank correlation or Mann-Whitney U test, as appropriate).
yAll treated successfully with PCI.
FIGURE 1. Procedures versus calendar time according to surgeon. Of 5
surgeons, the first and most experienced performed first 100 procedures.
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628 patient-years. At the last data collection, 374 patients
(74.8%) were alive and 126 (25.2%) had died during the
follow-up period. The patient characteristics are summa-
rized in Appendix Table 1.
Procedures and proctoring. A total of 500 transapical
TAVI procedures were performed within 43.8 months. For
each subgroup of 100 patients, the duration was 12.4, 9.8,
8.0, 7.7, and 5.6 months, respectively. Of the 5 surgeons,
the oldest and first operator performed 221 (44.2%) proce-
dures (Figure 1). Three other operators started after 100 pro-
cedures and performed 116 (23.2%), 71 (14.2%), and 84
(16.8%) procedures, respectively. The fifth operator started
after 441 procedures and operated on 8 patients (1.6%;The Journal of Thoracic and CaKruskal-Wallis test, P<.001 for the different periods of op-
erators; Figure 1). Surgeon 1 participated in 30% (119/
400), 7.5% (30/400), and 4% (10/400) of the procedures
as the first, second, and third assistant, respectively. Of
the 472 patients without cardiogenic shock, 203 (43%),
107 (22.7%), 70 (14.8%), 84 (17.8%), and 8 (1.7%) under-
went surgery by surgeons 1 to 5, respectively. Of the 28 pa-
tients with cardiogenic shock, 18 (64.3%), 9 (32.1%), and 1
(3.8%) underwent surgery by surgeons 1 to 3, respectively.
Segment 1 of the internal proctoring was performed for the
first 100 indexed procedures and subsequently only by re-
quest. Segment 2 was applied for 300 cases and later only
occasionally, according to the CUSUM charts or by request.
Segment 3 was performed in the phases according to the
CUSUM charts. Segment 4 was performed for 400 proce-
dures and then occasionally.
Procedural characteristics. The intraprocedural and post-
procedural data are listed in Table 1. Edwards Sapien THV
valves were used in 406 study patients (81.2%) and Ed-
wards Sapien XT valves in 94 (18.8%). Combined planned
percutaneous coronary intervention (PCI) was used in 57
patients (11.4%), and cardiopulmonary bypass (CPB) was
electively used in 25 (5%). Of the 500 patients, 11
(2.2%) underwent additional combined conventional car-
diac surgery. Four conversions (0.8%) were required to
conventional aortic surgery (three for annular rupture).
The final paravalvular or transvalvular regurgitation grade
was 0.4  0.5 (range, 0-2).
Thirty-day mortality. The overall 30-day mortality rate
for the whole study cohort of 500 patients was 4.6%
(95% CI, 3.1%-6.8%), with 23 deaths among the 500rdiovascular Surgery c Volume 145, Number 4 913
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tients without cardiogenic shock was 4.0% (95% CI,
2.6%-6.2%; 19 deaths among 472 patients). Among the
28 patients who underwent TAVI in cardiogenic shock, 4
died during the first 30 days (14.3%; 95% CI, 5.7%-
31.5%; Fisher’s exact test, P ¼ .03 vs patients without
shock). Throughout the study period, no significant change
was seen in 30-day mortality (Mann-Whitney U test,
P ¼ .23; logistic regression odds ratio, 0.83 per 100 pa-
tients; 95% CI, 0.62-1.12; P ¼ .23). No difference was
seen in 30-day mortality when stratified by surgeon
(Fisher’s exact test, P ¼ .92).
The series of 100 patients with the greatest 30-day mor-
tality rate during the study period was between indexed pro-
cedures 258 and 357, with mortality of 8.0% (8 of these 100
consecutive patients died). The series of 100 patients with
the lowest 30-day mortality rate per 100 consecutive pa-
tients (1.0%) was found between indexed procedures 358
and 463. (In this series between indexed procedures 358
and 463, when all 105 consecutive patients were included,
the mortality was 0.9%, with 1 death.) One series of 75 con-
secutive patients (between indexed procedure 358 and 432)
had no deaths within 30 days after the index procedure (30-
day mortality, 0%). No mortality occurred among the first
11 patients. The last death (indexed procedure 499) oc-
curred intraoperatively. A total of 8 patients (1.6%) died in-
traoperatively. The 30-day mortality in the 5 subgroups of
each 100 consecutive patients was 6%, 6%, 3%, 5%,
and 3%.
Changes in patient characteristics during study period.
Differences in the demographic characteristics of the
treated patients were seen in the percentages of men and
women and the risk profile of the patients, as mirrored by
the risk scores. During the study period, a significant in-
crease occurred in the percentage of male patients (Mann-
Whitney U test, P¼ .002) and a reduction in the risk scores
(logistic European System for Cardiac Operative Risk Eval-
uation, Society of Thoracic Surgeons predicted risk of mor-
tality, Society of Thoracic Surgeons morbidity or mortality
risk; Spearman rank correlation for each variable, P<.001).
However, bivariate logistic regression analysis demon-
strated that these changes in patient characteristics did not
influence the learning curves of 30-day mortality.
Procedural characteristics with no changes through
study period. No significant changes were seen in the
mean rates of elective PCI (P ¼ .95), elective use of CPB
(P ¼ .48), and emergency use of CPB (P ¼ .62). Also, no
significant changes were seen in the mean duration of the
induction of anesthesia (Spearman’s rho, 0.05; P ¼ .25),
amount of contrast volume used per procedure (rho, 0.09;
P¼ .053), number of repeat ballooning procedures for para-
valvular leakage (Mann-Whitney U test, P ¼ .38), final re-
gurgitation grade (rho, 0.06; P ¼ .16), intensive
care unit stay (rho, 0.06; P ¼ .15), intermediate care914 The Journal of Thoracic and Cardiovascular Surgstay (rho, 0.005; P ¼ .91), postoperative blood drainage
(rho, 0.005; P ¼ .91), or mean numbers of units of blood,
fresh frozen plasma, or thrombocytes given.
Procedural characteristics with changes during study
period. The procedure duration, radiation time, postopera-
tive ventilation time, and hospital stay at our institution de-
creased during the study period (P<.001 for all variables).
Also, a significant reduction was seen in the use of a second
Edwards Sapien valve during the same procedure
(P ¼ .006).
Technical procedural complications during study pe-
riod. The incidence of surgical complications occurring
during the technical part of the procedure was very low
(Table 1) and included revision for bleeding in 7 (1.4%; in-
dexed procedure 17, 20, 53, 104, 282, 333, and 389), surgi-
cal revision of apical pseudoaneurysm in 2 (0.4%; indexed
procedure 109 and 261), iatrogenic aortic dissection in 1
(0.2%; indexed procedure 413; treated by transapical place-
ment of an uncovered aortic endostent; patient survived16),
and valve migration in 1 patient (0.2%; indexed procedure
499; patient died intraoperatively). Annular rupture oc-
curred in 6 patients (1.2%; indexed procedure 60, 169,
259, 305, 422, and 423), with 3 deaths.11 Because few
events occurred per risk factor, the number of events was
not sufficient to enable accurate statistical analysis.18
Late survival. The overall 6-month, 1-year, and 2-year
survival rate was 83.9%  1.7%, 80.1%  1.9%, and
68.4%  2.7%, respectively, for the whole group
(Figure 2). An insignificant change was seen toward im-
proved overall survival during the study period, with
a 10.3% reduction in mortality per 100 procedures (hazard
ratio, 0.90; 95% CI, 0.77-1.04; P ¼ .15). No differences
were seen in survival when stratified by surgeon (log-rank
test, P ¼ .22; Figure 2).
Association of baseline and procedural characteristics
with survival. The patients had increased 30-day mortality
if they were in cardiogenic shock at surgery (P ¼ .03), if
conversion to conventional valve surgery was performed
(P ¼ .01), and if emergency CPB was used (P< .001).
No difference was seen in overall survival between the
male and female patients (P ¼ .52; Figure 2), if elective
PCI (P ¼ .73) or emergency PCI (P ¼ .17) was performed,
if a different valve was used (THV vs XT, P ¼ .59), or if
valve repeat ballooning was performed (P ¼ .13). Univari-
ate analysis revealed that the variables age (P ¼ .13), logis-
tic European System for Cardiac Operative Risk Evaluation
score (P¼ .12), and Society of Thoracic Surgeons predicted
operative mortality score (P ¼ .14) were not conjunct with
the 30-day mortality. An increased procedure duration
(P<.001), radiation time (P ¼ .05), intraoperative blood
and blood products given (P< .001 for packed red blood
cell units and P ¼ .02 for thrombocyte units given), and
postoperative fresh frozen plasma application (P< .001)
were related to increased 30-day mortality. However, theery c April 2013
FIGURE 2. Kaplan-Meier survival functions of A, whole cohort of 500 patients and subgroups of patients (Pts.) B, according to surgeon, C, patients with
and without cardiogenic shock, and D, according to gender.
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occurring during the procedure rather than the cause of
death. Owing to the small number of deaths, nomultiple sta-
tistical evaluation was performed.
CUSUM evaluation. The CUSUM failure graph
(Figure 3) showed no increase in 30-day mortality at the be-
ginning that could be expected in a classic learning curve.16
The chart demonstrated a cluster of deaths after indexed
procedure 100, after 175, and after 300 (Figure 3) that cor-
related with the point of a reduction in the level of internal
proctoring and forced reintroduction of a greater level of in-
ternal proctoring. The Hosmer-Lemeshow test did not de-
tect any violation of a constant odds ratio (P ¼ .60),
demonstrating an adequate immediate reaction.
Assessment of learning curve. The logistic learning curve
(Figure 4) demonstrated the absence of the typical greater
values (ie, absence of increased mortality) at the beginning
that could be expected in a classic learning curve.16
DISCUSSION
Themain result of the present study was the evidence that
the cumulative knowledge from the field incorporated into
a structured training program can be used for initial intro-
duction of a novel technique—transapical TAVI—intoThe Journal of Thoracic and Caclinical institutional practice and can be gradually dispersed
by internal proctoring to other members of the team without
negative effects on the clinical outcome. This program re-
sulted in lower-than-expected 30-day mortality and a low
technical complication rate from the beginning, remaining
consistent throughout a series of 500 procedures. The neg-
ative effect of the learning curve was absent both for the
whole team and individually for each surgeon. Therefore,
the study results strongly recommend that a prospective
TAVI team should undergo a structured and intensive train-
ing program before starting clinical application of TAVI.
An additional and important negative observation of the
present study was that early mortality is increased if an in-
traprocedural complication occurs, requiring conversion to
conventional surgery or even only institution of emergency
CPB.
Cumulative Knowledge From the Field and the
Learning Curve
A typical learning curve shows the ‘‘learning phase’’ at
the beginning, with increased mortality or complication
rate, the ‘‘intermediate phase,’’ with decreasing overall
complication and mortality rates, and, finally, the ‘‘expert
phase,’’ characterized by low rates.16 In terms of mortality,rdiovascular Surgery c Volume 145, Number 4 915
FIGURE 3. Unadjusted cumulative failure chart with 30-day mortality of
study cohort showing clusters of failure (deaths) during short period after
indexed procedure 100, 175, and 300 correlating with point of reduction
of internal proctoring (and forcing a return to a greater level of internal
proctoring).
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lieve to be mostly because of the structured training pro-
gram that encompassed the cumulative knowledge and
experience of the ‘‘first-wave’’ centers. The ‘‘first-wave’’
centers had elevated mortality during their early experience
compared with their recent experience,1-5,7 and their results
fit into the classic learning curve. The initial mortality
during the learning curve might be double that during the
expert phase. The Leipzig group4 showed a reduction in
30-day mortality from 11.3% to 6%, comparing their firstFIGURE 4. Learning curve of 30-day mortality (logistic regression anal-
ysis) showing absence of typical greater values (ie, absence of mortality in-
crease) at beginning. No significant change seen in 30-day mortality
throughout study period.
916 The Journal of Thoracic and Cardiovascular Surg150 patients with their subsequent 149 patients and with
progressive improvement in outcomes despite an un-
changed patient risk profile. It seems that each member (op-
erator) of the team needs—in general—at least 50 to 100
procedures to reach the expert phase. Thus, the more oper-
ators/members, the longer the learning curve. However,
only a few reports have been published about the ‘‘learning
curve for TAVI.’’1-8,19 Most of them have studied, logically,
only a small number of patients. The largest reported
experience was of 299 patients.4 Among the ‘‘first-wave’’
centers with extensive experience with the novel procedure
(>100 procedures), the Leipzig group4 also had the lowest
30-day mortality rate during their recent experience (6%).
Length of Our TAVI Learning Curve
The results from the present study failed to find a com-
plete answer to this question. In terms of the primary end-
point (30-day mortality), the present study has clearly
demonstrated the absence of increased mortality throughout
the study period. However, in terms of the secondary end-
points, our results only gave a partially positive answer. Al-
though the observed technical procedural complication rate
was already low from the beginning of the TAVI program,
the study results confirmed that a small, but certain, number
of patients would—throughout the study period—have
a possibly detrimental intraprocedural complication (eg, an-
nular rupture) that is difficult to manage. This is the main
disadvantage of TAVI compared with conventional aortic
valve surgery. Therefore, the main problem of TAVI re-
mains—the uncertainty about the definitive result at the
end of the procedure. Similarly, it is still not possible to pre-
dict clearly whether a patient undergoing TAVI will have
relevant paravalvular leakage (with known negative conse-
quences for late survival and a reason for preferring conven-
tional aortic valve surgery). Additionally, the effect on
cognitive function of cerebral microembolization and the is-
chemic microlesions that always occur during all phases of
valve implantation20 remains to be defined. Therefore, we
believe we are still in the learning curve. All these factors
should be considered critically before the procedural indi-
cation is broadened to younger or lower risk patients.
Importance of Heart Team for Prospective
Cardiovascular Training
The present study has emphasized the importance of the
combined work of surgeons and cardiologists in a team. Our
team was able to perform all types of TAVI procedures and
conventional aortic valve surgery21 and to treat its own pro-
cedural complications using surgical or catheter-based
methods.11,17,22,23 Thus, 1 team was able to perform the
procedure assessed to be the best for each patient. This
attitude should have important consequences for the
education and training of prospective cardiologists and
surgeons. Therefore, in the future, cardiovascular trainingery c April 2013
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both a cardiologist and a conventional cardiovascular
surgeon. A prospective cardiovascular specialist should be
able to perform all types of catheter-based and conventional
surgery, including managing all complications using both
procedures. Complications will be managed mostly using
a catheter-based technique,17,22 with surgical revision
needed only if the interventional method is not possible or
fails to treat the complication.11,23Study Limitations
The study possessed several limitations. The main limita-
tions were the retrospective study design and the lack of
a comparable study group. However, the data were prospec-
tively collected and timely analyzed with immediate clini-
cal consequences. Despite this, a prospective study with
a control group would make possible the comparison be-
tween proctored and nonproctored cases. Therefore, a pro-
spective study is needed. An additional important limitation
was that the device-related factors (using a modified type of
valve during the experience) could have some influence
(negative or positive) on the results.CONCLUSIONS
Transapical TAVI could be a valid step toward the ulti-
mate goal of replacing the aortic valve without surgery,
but the procedure itself still needs its own learning curve.
Thus, the study results strongly recommend a structured
and intensive training program before starting clinical ap-
plication of TAVI.
The other members of our TAVI team were Christoph Klein,
MD, Ekatarina Ivanitskaia-K€uhn, MD, Guna Tetere, MD, Tom
Gromann, MD, Katrin Sch€afer, and Natalia Solowjowa, MD. We
thank Anne Gale for editorial assistance and Rosemarie G€unther
for secretarial support, Christine Detschades and Michael Regitz
for data acquisition, and Helge Haselbach for graphic support.
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APPENDIX TABLE 1. Preoperative characteristics of study cohort
(n ¼ 500)
Parameter Value P value*
Male 189 (37.8) .002
Female 311 (62.2) .002
Height (cm) 165 (160-171) .03
Weight (kg) 72.5 (62-82) .01
Body mass index (kg/m2) 26.6 (23.6-29.7) .28
NYHA class IV 169 (33.8) .10
Age (y) 80.6 (75.3-84.6) .97
FEV1 (L) 1.5 (1.2-1.9) .01
FEV1 (%) 74 (59-90) .05
Creatinine (mg/dL) 1.1 (0.85-1.3) .04
Creatinine clearance (mL/min) 50.9 (36.9-65.9) .001
Dialysis 15 (3) 1.0
NT-proBNP (pg/mL) 2146 (1031-5118) .01
Troponin I (mg/mL) 0.02 (0.01-0.05) <.001
Cardiogenic shock 28 (5.6) .34
Logistic EuroSCORE (%) 30.4 (21.1-48.5) <.001
STS PROM score (%) 12.2 (6.7-21.5) <.001
STS MoM score (%) 40.9 (30.0-58.3) <.001
Atrial fibrillation 14.5  29.0 .03
Pacemaker/ICD 57 (11.4) .50
Previous aortic valve replacement 27 (5.4) .58
Previous coronary bypass surgery 87 (17.4) .24
Previous mitral valve replacement 12 (2.4) .54
Stroke/cerebral lesion 113 (22.6) <.001
Peripheral arterial disease 342 (68.4) .22
Chronic pulmonary obstructive disease 240 (48.0) .10
Systolic PAP>50 mm Hg 179 (35.8) .26
Diabetes mellitus 140 (28.0) <.001
Renal failure 121 (24.2) .03
Coronary artery disease 301 (60.2) .09
Previous PCI 93 (18.6) <.001
Left ventricular ejection fraction (%) 55 (40-60) .77
LVEDD (mm) 48 (44-54) .30
dPmax (mm Hg) 73 (60-85) .45
dPmean (mm Hg) 50 (40-56) .55
Aortic valve area (cm2) 0.6 (0.6-0.8) .24
Annulus/TEE (mm) 22.4 (21.1-23.3) <.001
Annulus/CT (mm) 23.0 (21.9-24.3) .37
Bicuspid aortic valve 13 (2.6) .003
Severe calcified ascending aorta 69 (13.8) <.001
Data are presented as mean  standard deviation, n (%), or median (interquartile
range).NYHA,NewYork Heart Association; FEV1, forced expiratory volume in 1 sec-
ond; NT-proBNP, N-terminal probrain natriuretic peptide; EuroSCORE, European
System for Cardiac Operative Risk Evaluation; STS, Society of Thoracic Surgeons;
PROM, predicted operativemortality;MoM,mortality or morbidity; ICD, implantable
cardiodefibrillator; PAP, pulmonary artery pressure; PCI, percutaneous coronary in-
tervention; LVEDD, left ventricular end-diastolic diameter; dPmax, maximal trans-
valvular gradient, dPmean, mean transvalvular gradient; TEE, transesophageal
echocardiography; CT, computed tomography. *For changes during study period
(Spearman rank correlation or Mann-Whitney U test, as appropriate).
APPENDIXTABLE 2. Thirty-dayoutcomes according to standardized
endpoint definitions for TAVI clinical trials of Valve Academic Research
Consortium
Parameter n (%)
All-cause mortality 23 (4.6)
Cardiovascular mortality 21 (4.2)
Periprocedural myocardial infarction 3 (0.6)
Spontaneous myocardial infarction 2 (0.4)
Major stroke 5 (1.0)
Minor stroke 5 (1.0)
Life-threatening bleeding 18 (3.6)
Minor vascular complication 4 (0.8)
Major vascular complication 18 (3.6)
Renal dialysis 18 (3.6)
Combined safety endpoint 85 (17.0)
Permanent pacemaker 28 (5.6)
TAVI, Transcatheter aortic valve implantation.
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